文献速递心力衰竭与心肌病

CAR-T治疗患者生物标志物与心血管结局的关联

Biomarkers and cardiovascular outcomes in chimeric antigen receptor T-cell therapy recipients.
PubMed 文献 · Eur Heart J · 2023-01-01

该多中心注册研究纳入202例接受抗CD19 CAR-T治疗的患者,分析CAR-T相关严重心血管事件(SCE)与死亡率的关系。SCE与全因死亡(HR 2.8,95%CI 1.6-4.7)及非复发死亡(HR 3.5,95%CI 1.4-8.8)独立相关,且死亡者峰值IL-6和铁蛋白更高。

要点

  • 死亡患者CAR-T输注后峰值IL-6和铁蛋白水平更高。
  • 发生SCE者峰值IL-6、CRP、铁蛋白和肌钙蛋白水平更高。

核心结论

  • CAR-T治疗后发生严重心血管事件的患者全因死亡和非复发死亡风险更高,且峰值IL-6、CRP、铁蛋白和肌钙蛋白水平更高。

研究设计与样本

  • 多中心注册研究纳入202例接受抗CD19 CAR-T治疗的患者,收集体重基线心血管和癌症参数及生物标志物。
  • 严重心血管事件定义为心力衰竭、心源性休克或心肌梗死的复合终点。
  • 中位随访297天(四分位距104-647天)。

主要发现

  • 死亡者与未死亡者在年龄、性别和既往蒽环类药物使用方面相似。
  • 死亡者CAR-T输注后峰值IL-6和铁蛋白水平更高。
  • 发生SCE者峰值IL-6、CRP、铁蛋白和肌钙蛋白水平更高。
  • 第100天和1年Kaplan-Meier总死亡率估计分别为18%和43%,非复发死亡累积发生率分别为3.5%和6.7%。

关键数值与推荐

  • Cox模型校正年龄、癌症类型和负荷、蒽环类药物使用、细胞因子释放综合征≥2级、既往心力衰竭、高血压和非裔美国人血统后,SCE与全因死亡风险增加独立相关(HR 2.8,95%CI 1.6-4.7)。
  • 校正癌症负荷后,SCE与非复发死亡风险增加独立相关(HR 3.5,95%CI 1.4-8.8)。

临床怎么用

  • CAR-T治疗患者应监测IL-6、CRP、铁蛋白和肌钙蛋白等生物标志物。
  • 发生严重心血管事件的患者需加强死亡风险评估和随访管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Chimeric antigen receptor T-cell therapy (CAR-T) harnesses a patient's immune system to target cancer. There are sparse existing data characterizing death outcomes after CAR-T-related cardiotoxicity. This study examines the association between CAR-T-related severe cardiovascular events (SCE) and mortality. METHODS AND RESULTS: From a multi-centre registry of 202 patients receiving anti-CD19 CAR-T, covariates including standard baseline cardiovascular and cancer parameters and biomarkers were collected. Severe cardiovascular events were defined as a composite of heart failure, cardiogenic shock, or myocardial infarction. Thirty-three patients experienced SCE, and 108 patients died during a median follow-up of 297 (interquartile range 104-647) days. Those that did and did not die after CAR-T were similar in age, sex, and prior anthracycline use. Those who died had higher peak interleukin (IL)-6 and ferritin levels after CAR-T infusion, and those who experienced SCE had higher peak IL-6, C-reactive protein (CRP), ferritin, and troponin levels. The day-100 and 1-year Kaplan-Meier overall mortality estimates were 18% and 43%, respectively, while the non-relapse mortality (NRM) cumulative incidence rates were 3.5% and 6.7%, respectively. In a Cox model, SCE occurrence following CAR-T was independently associated with increased overall mortality risk [hazard ratio (HR) 2.8, 95% confidence interval (CI) 1.6-4.7] after adjusting for age, cancer type and burden, anthracycline use, cytokine release syndrome grade ≥ 2, pre-existing heart failure, hypertension, and African American ancestry; SCEs were independently associated with increased NRM (HR 3.5, 95% CI 1.4-8.8) after adjusting for cancer burden. CONCLUSION: Chimeric antigen receptor T-cell therapy recipients who experience SCE have higher overall mortality and NRM and higher peak levels of IL-6, CRP, ferritin, and troponin.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Mahmood, Riedell, Feldman, et al. Biomarkers and cardiovascular outcomes in chimeric antigen receptor T-cell therapy recipients. Eur Heart J. 2023. PMID: 36939851. doi:10.1093/eurheartj/ehad117

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。